AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03104998
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
Trial: NCT02209649
Drug: Lacidipine and Telmisartan fixed dose combination (FDC) tablet
RxNorm normalized name: LACIDIPINE
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02209649
Drug: Lacidipine
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02209649
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00818571
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
Trial: NCT00818571
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
Trial: NCT00818571
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Matching healthy volunteers receiving 25 mg vildagliptin once daily.
Trial: NCT00818571
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Matching healthy volunteers receiving 50 mg vildagliptin once daily
Trial: NCT00676793
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four 200mg capsules daily taken with a meal, for the duration of the study.
Trial: NCT05396898
Drug: twice-daily tacrolimus
RxNorm normalized name: clindamycin
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
Trial: NCT00700895
Drug: Warfarin Sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
Trial: NCT04529135
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Trial: NCT03786887
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage of nalbuphine
Trial: NCT02728700
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02728700
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02172807
Drug: Tiotropium low
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg inhalation capsule
Trial: NCT02172807
Drug: Tiotropium high
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 36 µg inhalation capsule
Trial: NCT02172807
Drug: Oxitropium
RxNorm normalized name: oxitropium
DrugBank: Oxitropium (DB12086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium MDI (100 µg/puff)
Trial: NCT03815461
Drug: Nab-paclitaxel and S-1
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
Trial: NCT00168324
Drug: 700 µg Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Trial: NCT00168324
Drug: 350 µg Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350 µg Dexamethasone intravitreal implant administered on Day 0.
Trial: NCT01445106
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01445106
Drug: Nelfinavir Mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003809
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02168881
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01263093
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03185104
Drug: Silver Diamine Fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
Trial: NCT03185104
Drug: Distilled Water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
Trial: NCT01661166
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg
Trial: NCT01699412
Drug: Clobetasol
RxNorm normalized name: Clobetasol
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
Trial: NCT01699412
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
Trial: NCT00120289
Drug: Extended release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 mg/day or 1,500 mg/day if higher dose not tolerated
Trial: NCT03288740
Drug: Semaglutide 0.5 mg
RxNorm normalized name: semaglutide 0.5 MG/ML
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Trial: NCT03288740
Drug: Placebo (semaglutide 0.5 mg)
RxNorm normalized name: semaglutide 0.5 MG/ML
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Trial: NCT03288740
Drug: Semaglutide 1.0 mg
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Trial: NCT03288740
Drug: Placebo (semaglutide 1.0 mg)
RxNorm normalized name: semaglutide 1 MG/ML
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Trial: NCT02818140
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02818140
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02131545
Drug: Quetiapine 25 mg gel applied topically
RxNorm normalized name: quetiapine 25 MG
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
Trial: NCT02131545
Drug: Quetiapine 25 mg tablet by mouth
RxNorm normalized name: quetiapine 25 MG
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
Trial: NCT02131545
Drug: Quetiapine 25 mg rectal suppository
RxNorm normalized name: quetiapine 25 MG
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
Trial: NCT02131545
Drug: Quetiapine 25 mg gel applied topically
RxNorm normalized name: quetiapine 25 MG
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
Trial: NCT01040338
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
Trial: NCT01194869
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
Trial: NCT01194869
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² given IV
Trial: NCT01194869
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m² given IV
Trial: NCT02858973
Drug: Q203
RxNorm normalized name: Telacebec
DrugBank: Telacebec (DB17754)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04518982
Drug: Sintilimab and lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
Trial: NCT04518982
Drug: Sintilimab placebo and lenalidomide placebo
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
Trial: NCT00614653
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg IV Over 90 Minutes Every 2 Weeks
Trial: NCT00614653
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth Once Daily on days with radiation.
Trial: NCT00699842
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days
Trial: NCT00386490
Drug: larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule for oral administration
Trial: NCT02705768
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
Trial: NCT00085917
Drug: Double dose pegylated interferon with weight based Ribavirin
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
Trial: NCT00085917
Drug: standard dose pegylated interferon alfa -2a and ribavirin
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
Trial: NCT00722709
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
Trial: NCT00000450
Drug: Naltrexone Tablet
RxNorm normalized name: naltrexone Oral Tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04627012
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Trial: NCT04627012
Drug: Opdivo
RxNorm normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/mg intravenously every 3 weeks
Trial: NCT04627012
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks
Trial: NCT04627012
Drug: Keytruda
RxNorm normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg intravenously every 3 weeks
Trial: NCT04627012
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg intravenously every 3 weeks
Trial: NCT04627012
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks
Trial: NCT04627012
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks
Trial: NCT01668030
Drug: Bacitracin
RxNorm normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00089479
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 iv on day 1 of each 3 week cycle
Trial: NCT00089479
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/m2 iv on day 1 of each 3 week cycle
Trial: NCT02780479
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: at 24 hours from the first Dexamethasone dose given in ED.
Trial: NCT02780479
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at 24 hours from the first Dexamethasone dose given in ED.
Trial: NCT03109756
Drug: OV101
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 5 mg OV101
Trial: NCT00403819
Drug: Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)
RxNorm normalized name: polyethylene glycol 3350 / potassium chloride / sodium bicarbonate / sodium chloride
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04278508
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
Trial: NCT01958879
Drug: ringer with corticosteroid
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
Trial: NCT04162535
Drug: Lidocaine 1% Injectable Solution
RxNorm normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop
Trial: NCT04162535
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
Trial: NCT04162535
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a general anesthesia with Propofol as anesthetic agent
Trial: NCT03360045
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
Trial: NCT01497535
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
Trial: NCT01497535
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
Trial: NCT02776501
Drug: Coppertone (BAY987521)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
Trial: NCT00779311
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
Trial: NCT00779311
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
Trial: NCT01319916
Drug: ATX-101
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 2mg/cm2
Trial: NCT00335998
Drug: triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00335998
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01511107
Drug: Amoxicillin-Clavulanate, 10 days
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
Trial: NCT01804036
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
Trial: NCT02199613
Drug: Treatment simplification
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.